Role of antioxidant therapy in patients with moderate and severe COVID-19

Q4 Medicine

Infektsionnye Bolezni Pub Date : 2021-01-01 DOI:10.20953/1729-9225-2021-1-159-164

E. Shavarova, E. R. Cazahmedov, M. Alekseeva, L. Ezhova, Z. Kobalava

{"title":"Role of antioxidant therapy in patients with moderate and severe COVID-19","authors":"E. Shavarova, E. R. Cazahmedov, M. Alekseeva, L. Ezhova, Z. Kobalava","doi":"10.20953/1729-9225-2021-1-159-164","DOIUrl":null,"url":null,"abstract":"The coronavirus disease COVID-19 is characterized by high mortality and the lack of effective etiotropic therapy. Activation of oxidative stress may be one of the links in the pathogenesis of organ damage of this infection. Objective. To assess the ability of Mexidol® to influence the rate of clinical improvement in pneumonia caused by the SARSCoV-2 virus in hospitalized patients with the novel coronavirus disease COVID-19 and concomitant discirculatory encephalopathy. 62 patients over the age of 18 years with confirmed new coronavirus disease COVID-19 according to computed tomography (CT) of the lungs (stages CT1, CT2, CT3) and PCR of a swab from the nasopharynx and oropharynx for SARS-CoV-2 virus RNA were included. After randomization patients of group 1 received an infusion of Mexidol® at a dose of 1000 mg/day, patients of group 2 – an infusion of isotonic sodium chloride solution for 7 days. Compared with the control group, the patients receiving Mexidol® therapy showed a significantly more pronounced decrease in body temperature, a tendency towards a decrease in the severity of shortness of breath. In the Mexidol® group, the concentration of superoxidedismutase did not change, while in the control group there was a tendency to its decrease, C-reactive protein decreased 2.2 times more than in the control group (p = 0.09). There was a tendency for a more rapid decrease in ferritin in the active intervention group. Mexidol® therapy can have a positive effect on the clinical manifestations and severity of laboratory-inflammatory syndrome in patients with the new coronavirus disease COVID-19. Key words: coronavirus disease COVID-19, oxidative stress, Mexidol","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2021-1-159-164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 8

Abstract

The coronavirus disease COVID-19 is characterized by high mortality and the lack of effective etiotropic therapy. Activation of oxidative stress may be one of the links in the pathogenesis of organ damage of this infection. Objective. To assess the ability of Mexidol® to influence the rate of clinical improvement in pneumonia caused by the SARSCoV-2 virus in hospitalized patients with the novel coronavirus disease COVID-19 and concomitant discirculatory encephalopathy. 62 patients over the age of 18 years with confirmed new coronavirus disease COVID-19 according to computed tomography (CT) of the lungs (stages CT1, CT2, CT3) and PCR of a swab from the nasopharynx and oropharynx for SARS-CoV-2 virus RNA were included. After randomization patients of group 1 received an infusion of Mexidol® at a dose of 1000 mg/day, patients of group 2 – an infusion of isotonic sodium chloride solution for 7 days. Compared with the control group, the patients receiving Mexidol® therapy showed a significantly more pronounced decrease in body temperature, a tendency towards a decrease in the severity of shortness of breath. In the Mexidol® group, the concentration of superoxidedismutase did not change, while in the control group there was a tendency to its decrease, C-reactive protein decreased 2.2 times more than in the control group (p = 0.09). There was a tendency for a more rapid decrease in ferritin in the active intervention group. Mexidol® therapy can have a positive effect on the clinical manifestations and severity of laboratory-inflammatory syndrome in patients with the new coronavirus disease COVID-19. Key words: coronavirus disease COVID-19, oxidative stress, Mexidol

查看原文本刊更多论文

抗氧化治疗在中重度COVID-19患者中的作用

冠状病毒病COVID-19的特点是死亡率高，缺乏有效的致病因治疗。氧化应激的激活可能是该感染引起器官损伤的发病机制之一。目标。评估Mexidol®对新型冠状病毒病COVID-19合并循环性脑病住院患者SARSCoV-2病毒引起的肺炎临床改善率的影响。本研究纳入了62例年龄在18岁以上，经肺部计算机断层扫描(CT) (CT1、CT2、CT3期)和鼻咽和口咽拭子PCR检测SARS-CoV-2病毒RNA的确诊新型冠状病毒COVID-19患者。随机分组后，1组患者输注剂量为1000 mg/天的Mexidol®，2组患者输注等渗氯化钠溶液，持续7天。与对照组相比，接受Mexidol®治疗的患者表现出明显更明显的体温下降，呼吸短促的严重程度有降低的趋势。在Mexidol®组中，超氧化物歧化酶的浓度没有变化，而在对照组中，超氧化物歧化酶的浓度有下降的趋势，c反应蛋白的下降是对照组的2.2倍(p = 0.09)。在积极干预组中，铁蛋白有更快下降的趋势。Mexidol®治疗可对新型冠状病毒病COVID-19患者的临床表现和实验室炎症综合征的严重程度产生积极影响。关键词:冠状病毒病，氧化应激，墨西哥

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.